论文部分内容阅读
９０例垂体生长激素（ＧＨ）瘤患者，首发症状以面容变丑、肢端肥大最多，为８３例（９２％）。２８例（３１％）视力明显减退，２４例（２６．７％）双眼或单眼颞侧或外上象限偏盲，合并糖尿病和糖耐量减退共３３例（３６．７％）。９０例患者基础血清ＧＨ水平均＞５μｇ／Ｌ，其中＞８０μｇ／Ｌ者３４例。３９例行３ｈ１００ｇ葡萄糖抑制ＧＨ试验，１８例行阿托品抑制ＧＨ试验，两组患者ＧＨ水平均不能被抑制到＜５μｇ／Ｌ水平。８８例患者行头颅ＣＴ检查均发现垂体瘤，９０例患者经手术证实大腺瘤４１例（４５．６％），微腺瘤４９例（５４．４％）。肿瘤向鞍上池扩展者３３例。术后３３例患者接受放射治疗，术后或以后１～５年随诊中６２．８％患者血清ＧＨ水平正常（＜５μｇ／Ｌ），９２．３％的患者ＧＨ水平较术前下降。７例患者视力增加或视野扩大。手术并发症发生率为８．９％（８例）。
In 90 patients with pituitary growth hormone (GH) tumors, the first symptoms were ugly face and acromegaly, with 83 cases (92%). Visual acuity decreased significantly in 28 cases (31%), hemianopia in the temporal or outer quadrant of both eyes or monocular eyes in 24 cases (26.7%), diabetes mellitus and impaired glucose tolerance in 33 cases (36.7%). Baseline serum GH levels were >5 μg/L in 90 patients, and 34 patients were >80 μg/L. 39 patients underwent 3h100g glucose inhibition GH test and 18 patients underwent atropine inhibition GH test. The GH levels in both groups could not be suppressed to <5μg/L level. Eighty-eight patients underwent cranial CT examination and found pituitary adenomas. Among the 90 patients, 41 (45.6%) had macroadenomas confirmed by surgery and 49 (54.4%) had microadenomas. Thirty-three cases of tumors extended to the suprasellar cistern. After the surgery, 33 patients received radiation therapy. 62.8% of the follow-up patients or 1 to 5 years later had normal serum GH levels (<5 μg/L), and 92.3% had lower GH levels than before surgery. Visual acuity increased or visual field was enlarged in 7 patients. The incidence of surgical complications was 8.9% (8 cases).